Evidence for the involvement of the serotonergic 5-HT2A/C and 5-HT3 receptors in the antidepressant-like effect caused by oral administration of bis selenide in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 2, 2010, Pages 294-302

  Jesse, Cristiano R ^a   Wilhelm, Ethel A ^a   Bortolatto, Cristiani F ^a   Nogueira, Cristina W ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antidepressant; Bis selenide; Noradrenergic; Selenium; Serotonergic and dopaminergic receptors

Indexed keywords

2,3 BIS(4 CHLOROPHENYLSELANYL)PROP 2 EN 1 OL; 8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; FENCLONINE; FLUOXETINE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ONDANSETRON; PRAZOSIN; PROPRANOLOL; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; ENZYME ACTIVITY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILIZATION; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; OPEN FIELD TEST; SEROTONINERGIC SYSTEM; TAIL SUSPENSION TEST;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; HINDLIMB SUSPENSION; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MONOAMINE OXIDASE; ORGANOSELENIUM COMPOUNDS; PROPRANOLOL; RECEPTORS, SEROTONIN, 5-HT2; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGENTS; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS; SWIMMING; TIME FACTORS; YOHIMBINE;

EID: 77649276066     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.11.023     Document Type: Article

References (43)

1. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
2. Binfaré R.W., Rosa A.O., Lobato K.R., Santos A.R., Rodrigues A.L. Ascorbic acid administration produced an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:530-540.
3. Bourin M., Chenu F., Ripoll N., David D.J.P. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspensions tests. Behav Brain Res 2005, 164:266-269.
4. Burk R.F. Selenium, an antioxidant nutrient. Nutr Clin Care 2002, 5:75-79.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976, 72:248-254.
6. Brocardo P.S., Budni J., Kaster M.P., Santos A.R.S., Rodrigues A.L.S. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonertic and noradrenergic systems. Neuropharmacology 2008, 54:464-473.
7. Brunello N., Blier P., Judd L.L., Mendlewicz J., Nelson C.J., Souery D., et al. Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol 2003, 18:191-202.
8. Cunha M.P., Machado D.G., Bettio L.E.B., Capra J.C., Rodrigues A.L.S. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1913-1920.
9. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000, 405:365-373.
10. Deniker P. Psychopharmacology and biological psychiatry, historical review. Soins Psychiatr 1983, 37:5-6.
11. Eisensamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry 2003, 12:994-1007.
12. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
13. + ATPase hypothesis for bipolar illness. Biol Psychiatry 1995, 37:235-244.
14. Fiske C.H., Subbarow Y.J. The calorimetric determination of phosphorus. Biol Chem 1925, 66:375-381.
15. Hawkes W.C., Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatr 1996, 39:121-128.
16. Holtzheimer P.E., Nemeroff C.B. Advances in the treatment of depression. J NeuroRx 2006, 3:42-56.
17. Ishihara K., Sasa M. Potentiation of 5-HT3 receptor functions in the hippocampal CA1 region of rats following repeated electroconvulsive shock treatments. Neurosci Lett 2001, 307:37-40.
18. + channel pathways in the antinociceptive effect caused by 2,3-bis(mesitylseleno)propenol. Life Sci 2007, 81:1694-1702.
19. Jesse C.R., Savegnago L., Nogueira C.W. Spinal mechanisms of antinociceptive effect caused by oral administration of bis selenide in mice. Brain Res 2008, 1231:25-33.
20. Kaster M.P., Raupp I., Binfaré R.W., Andreatini R., Rodrigues A.L. Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system. Eur J Pharmacol 2007, 565:119-124.
21. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumim: involvement of serotonin and dopamine system. Psychopharmacology 2008, 201:435-442.
22. Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 1965, 14:1683-1685.
23. Krishnan K.R., Doraiswamy P.M., Figiel G.S., Husain M.M., Shah S.A., Na C., et al. Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci 1991, 3:387-391.
24. Matsumoto T., Furuta T., Nimura Y., Suzuki O. 3-(p-Hydroxyphenyl)propionic acid as a new fluorogenic reagent for amine oxidase assays. Anal Biochem 1984, 138:133-136.
25. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 2004, 500:371-384.
26. Moro A.V., Nogueira C.W., Barbosa N.B.V., Menezes P.H., Rocha J.B.T., Zeni G. Highly stereoselective one-pot producers to prepare bis- and tris chalcogenide alkenes via addition of disulfides and diselenides to terminal alkynes. J Org Chem 2005, 70:5257-5268.
27. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998, 55:580-592.
28. Nemeroff C.B., Owens M.J. Treatment of mood disorders. Nat Neurosci 2002, 5:1068-1070. Suppl.
29. Nestler E.J., Barrot M., Dileone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
30. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006, 16:391-402.
31. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
32. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356:23-41.
33. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., Rao B.S. Erythrocyte membrane sodium-potassium adenosine triphosphatase activity in affective disorders. J Neural Transm Gen Sect 1992, 89:209-218.
34. Redrobe J.P., Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997, 325:129-135.
35. Rodrigues A.L.S., Da Silva G.L., Mateussi A.S., Fernandes E.S., Miguel O.G., Yunes R.A., et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 2002, 70:1347-1358.
36. Savegnago L., Jesse C.R., Moro A.V., Borges V.C., Santos F.W., Rocha J.B.T., Nogueira C.W. Bis selenide alkene derivatives: a class of potential antioxidant and antinociceptive agents. Pharmacol Biochem Behav 2006, 83:221-229.
37. Shah B.H., Saeed S.A., Rashid F., Gilani A.H. Dopamine potentiation of calcium ionophore, A-23187-induced platelet aggregation. Adv Exp Med Biol 1997, 407:537-540.
38. Sher L. Depression and suicidal behavior in alcohol abusing adolescents: possible role of selenium deficiency. Minerva Pediatr 2008, 60:201-209.
39. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Sanchez-Sellero I., Cruz-Landeira A., Lamas L.M. Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals: potential implications in relation to oxidative stress. Life Sci 2001, 69:879-889.
40. Steffens D.C., Krishnan K.R., Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997, 6:10-18.
41. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
42. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
43. Zomkowski A.D.E., Hammes L., Lin J., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Agmatine produces antidepressant-like effects in two models of depression in mice. NeuroReport 2002, 13:387-391.